Verrica Pharmaceuticals (NASDAQ:VRCA) Issues Earnings Results

Verrica Pharmaceuticals (NASDAQ:VRCA) posted its quarterly earnings data on Monday. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12), Zacks reports. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The firm had revenue of ($1.78) million during the quarter, compared to analysts’ expectations of $7.53 million.

Verrica Pharmaceuticals Stock Performance

VRCA traded down $0.51 on Tuesday, hitting $0.92. 848,322 shares of the company’s stock were exchanged, compared to its average volume of 435,172. The firm has a market cap of $39.24 million, a PE ratio of -0.49 and a beta of 1.45. Verrica Pharmaceuticals has a twelve month low of $0.75 and a twelve month high of $11.41. The stock has a fifty day moving average of $1.71 and a two-hundred day moving average of $5.21. The company has a current ratio of 2.36, a quick ratio of 2.23 and a debt-to-equity ratio of 29.58.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Brookline Capital Management reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, October 2nd. Needham & Company LLC reaffirmed a “hold” rating and set a $12.00 price target on shares of Verrica Pharmaceuticals in a research report on Thursday, October 3rd. Royal Bank of Canada cut shares of Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Tuesday. Finally, TD Cowen reduced their price target on shares of Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, October 21st. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Verrica Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $11.40.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.